TP53 and neoplasm: Interestingly, LcPDXs showed enrichment in mutation rate of TP53 in all tumour types and of KRAS in ADC where the frequency of mutations was almost double than that expected from literature data (57.9% KRAS mutated PDX vs 25–35% KRAS mutated ADC31) whereas EGFR mutations were rarely present.